Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ALS-L1023 for nonalcoholic steatohepatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• ALS-L1023

Snippet

Sponsor: AngioLab, Inc. | Conditions: Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED